Supernus Pharmaceuticals reported a 14% increase in total revenue for Q3 2024, driven by strong sales of Qelbree and GOCOVRI. Operating earnings significantly improved compared to the same period in the previous year. The company also announced positive topline data from its Phase 2a study of SPN-820 in major depressive disorder and initiated a Phase 1 study for SPN-443.
Qelbree net sales increased by 68% compared to Q3 2023.
GOCOVRI net sales increased by 8% compared to Q3 2023.
Total revenues increased by 14% compared to Q3 2023.
Operating earnings improved significantly, reaching $40.9 million compared to $8.1 million in Q3 2023.
Supernus Pharmaceuticals is increasing its full year 2024 financial guidance for total revenues and operating earnings (GAAP and Non-GAAP).
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance